Results: 139 of 204 patients completed the survey (68%). The most prevalent symptom was pruritus (71.2%), with over 90% of peritoneal dialysis patients reporting this symptom. Next most common was “weakness or a lack of energy” (70.5%), and restless legs (69.7%). Of concern, moderate or severe pain was present in 66.7% of the conservatively

managed RXDX-106 patients, and in 25% overall. “Feeling depressed” was also self-reported in 43.9% of patients, with 60% of home haemodialysis and 58% of PD patients feeling depressed. Conclusions: Our results are similar to previous published reports, but this survey is one of the few which reports across a “whole of service” renal population. Renal patients suffer a significant symptom burden, and an important challenge is how to better support and reliably identify renal patients with high Src inhibitor symptom burdens. Shared care clinics with nephrologists, palliative specialists, nurses and other allied health staff are an increasingly common model of care. 217 A RETROSPECTIVE STUDY OF ANTI-GBM DISEASE AT WAIKATO HOSPITAL, NEW ZEALAND B MAHBUB, P SIZELAND Waikato Hospital, Hamilton, New Zealand Aim: To evaluate the efficacy of plasmapheresis in patients with anti GBM disease who presented with severe renal impairment in conjunction with extensive crescent formation on renal biopsy. Background: Anti GBM disease is a rare entity. It classically

presents with the syndrome of glomerulonephritis and/or pulmonary haemorrhage. The majority of patients have a combination of immunosuppression and plasmapheresis at the time of their diagnosis. Recent KDIGO guidelines do not support disease specific treatment in patients with severe AKI, 100% crescents on biopsy and no pulmonary haemorrhage. Meloxicam Methods: We reviewed patients (2001–2013) who had serologic and/or biopsy proven

anti GBM disease at Waikato Hospital using the hospital database. Results: 17 patients were identified. Age range was 16 to 81 (median of 47), 10 male and 7 female, 10 Maori and 7 European. One was noncompliant. 14 (82%) were ANCA negative. Anti GBM antibody titre ranged from 1:40 to 1:1280 with a median of 1:320. Serum creatinine level at presentation ranged from 70 to 2,080 with an average of 760 μmol/L. 12 (71%) had severe renal impairment (creatinine level of >500). 13 patients had 100% crescents, 3 did not have biopsy (normal renal function) and one biopsy was not available. 10 (59%) had pulmonary haemorrhage. All of our patients received immunosuppression and plasmapheresis. All patients with renal impairment at presentation required and remained on dialysis long term. 2 (12%) patients died, one within a month and the other one 8 years after diagnosis. Conclusions: Plasmapheresis has no effect on renal recovery in patients with anti GBM disease who have severe renal impairment.